AbbVie's commitment to racial justice

Racial injustice must end. Together, we must be a force for driving the accountability and change that we need to see in our society, both inside and outside AbbVie.

We are deeply concerned about the state of racial equality and social justice in the U.S. Each of us has to stand up and reject bias, racism and the lack of real inclusion. Read more about AbbVie's efforts.

CEO Richard Gonzalez’s letter to employees on racial justice

AbbVie's statement on racial injustice

Equality, diversity and inclusion

With a focus on recruiting, developing, retaining and performing, our equality, diversity & inclusion strategy enables us to raise the bar and continue growing. It includes driving awareness and understanding, attracting and sourcing talent, developing and engaging talent, and creating connections and community. Learn more

Clinical trial diversity 

AbbVie believes our clinical trials should reflect the global population as we aim to help patients live healthier, longer lives. Embracing diversity means we can better meet the needs of our patients today and tomorrow by incorporating a wide variety of perspectives as a key component of our scientific process. We are committed to researching and bringing treatment options for diseases that affect groups of patients who have historically been underserved, for whom in some cases no prior therapies existed. For example, in the area of women’s health,  AbbVie developed a first-in-class oral therapy for the treatment of endometriosis, a disease which affects about 1 in 10 women of reproductive age and causes significant impact on the quality of their daily lives. We recently gained approval for another related medicine for the treatment of uterine fibroids, a disease which disproportionately affects Black women.

Reducing health disparities

Black Americans face significant health disparities as a result of systemic inequalities, and as a biopharmaceutical company, it is our moral obligation to do all that we can to help reduce these disparities. Since we became a company seven years ago, we have developed new medicines and treatments for diseases that disproportionately impact Black communities. This includes a cure for Hepatitis C, as Black men and women aged 60 and older are 10 times more likely to be chronically infected with hepatitis C compared to other Americans. We’ve also developed the first oral medication for the management of heavy menstrual bleeding due to uterine fibroids. Black women suffer from a higher cumulative risk of uterine fibroids, a threefold greater incidence and relative risk of fibroids, and an earlier age of onset. Additionally, we have developed an oral treatment for chronic lymphocytic leukemia (CLL). Black patients with CLL are almost twice as likely to die from a CLL-related complication in the first 5 years after diagnosis as are Caucasian patients with CLL. But we are far from finished. We are working to develop new treatments that will significantly advance the standard of care for a number of diseases. 

Philanthropic support

Since our inception in 2013, AbbVie and the AbbVie Foundation have invested more than $120 million in philanthropic programs that purposefully support Black and marginalized communities in the United States. For example, we are addressing the achievement gap in our partnerships with Communities In Schools, City Year and the University of Chicago Education Lab, who are working to improve graduation rates, reduce dropout rates and boost college and career readiness for K-12. Through our employee volunteers and our donations, we’ve built school libraries across the U.S., processed and donated thousands of books, and increased access to STEM education. And in North Chicago, we’re building a brand-new middle school with a 21st century learning environment to improve student success. On June 16, 2020, we made a donation of $5 million to NAACP Legal Defense and Education Fund and the Equal Justice Initiative to address issues in our criminal justice system, and we’ve made an additional commitment of $50 million over five years to partner with nonprofits on a long-term, multi-faceted program that will seek to bring lasting and real change at the community level to help secure quality education, jobs, healthcare and justice. We’re also providing a 2:1 match for employees who wish to support organizations working to help address racial equality and social justice issues.

How to reach under-represented women in clinical trials


One of AbbVie’s medical directors connects with an often under-represented group of women to study uterine fibroids.

Read more

It's time to talk about uterine fibroids


Three health advocates bring awareness to what’s never been “normal”.

Read more

The value of education: from a dim reality to a bright future


Communities In Schools helped a boy living without electricity grow into a man with a master’s degree. Now he’s paying it forward.

Read more

Bringing STEAM education to the heart of Silicon Valley


After the bell rings, it’s time to unlock the potential in future scientists, artists and engineers. AbbVie partner City Year shows how it’s done.

Read more